Immunodiagnostics Market Report Scope & Overview:

The Immunodiagnostics Market was valued at USD 24.25 Billion in 2025 and is expected to reach USD 51.92 Billion by 2035, growing at a CAGR of 7.91% from 2026 to 2035.

The Immunodiagnostics Market continues to expand as growing incidence of chronic, infectious, and autoimmune diseases around the world primarily augments demand for immunodiagnostic testing. There is evidence of growth in market for immunodiagnosis as a result of innovations in biotechnology and advancements in diagnostic technology, whereby enzyme-linked immunosorbent assay, chemiluminescent immunoassays, and fluorescent immunoassays are some of the popular techniques revolutionizing the methods used in diagnostics by detecting antigen-antibody reactions necessary in the detection of many diseases. Significant focus on developing diagnostics, and the rising need for personalized medicine continues to create opportunities for the immunodiagnostic industry, where the WHO states that non-communicable diseases, which include autoimmune and cancer, were the cause of seventy-one percent of deaths globally in 2023.

The OPKO Health company has been issued approval by the United States Food and Drug Administration for their total prostate-specific antigen test that uses an immunoassay analyzer in November 2024. This has increased the testing capacity for OPKO and shows innovation in cancer biomarker detection technology.

Market Size and Forecast

• Market Size in 2026E: USD 26.17 Billion
• Market Size by 2035: USD 51.92 Billion
• CAGR: 7.91% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

To Get more information On Immunodiagnostics Market - Request Free Sample Report

Immunodiagnostics Market Trends

• Chemiluminescent and fluorescent immunoassay technologies continue transforming diagnostic methodologies alongside established ELISA techniques.
• Rising utilization of immunodiagnostics in rapid point-of-care testing devices continues expanding access beyond centralized laboratory settings.
• Collaborations and acquisitions continue serving as popular strategies for companies seeking to expand their immunodiagnostics business scope.
• United States tariff measures on imported diagnostic components are prompting manufacturers to pursue dual-sourcing and domestic production strategies.
• Rising utilization of immunodiagnostics in personalized medicine continues creating new business opportunities for testing providers.

The United States Immunodiagnostics Market Outlook

The United States Immunodiagnostics Market was valued at USD 8.51 Billion in 2025 and is expected to reach USD 18.20 Billion by 2035, growing at a CAGR of 7.90% from 2026 to 2035.

The United States maintained a leading position in North American immunodiagnostics demand, driven by the rising prevalence of infectious diseases, an increasing number of new product approvals, and the presence of adequate reimbursement for products and tests across the country. The sharp increase in United States tariffs and resulting trade tensions in spring 2025 significantly impacted the medical equipment sector, particularly for imported components, prompting manufacturers to mitigate risk through dual-sourcing and accelerated domestic production of standardized items.

Abbott, headquartered in Abbott Park, Illinois, continued expanding its immunodiagnostics testing portfolio in 2025, reinforcing its position as one of the world's leading diagnostic companies serving hospitals and laboratories across the American healthcare system with advanced immunoassay platforms.

Immunodiagnostics Market Segmentation Analysis

• By Product, the reagents consumables segment held approximately 45.60% share in immunodiagnostics market in 2025, while the instruments analyzers segment is the fastest growing.
• By Technology, the ELISA segment held approximately 36.40% share in immunodiagnostics market in 2025, while the chemiluminescent immunoassay segment is the fastest growing.
• By Application, the infectious diseases segment held approximately 31.20% share in immunodiagnostics market in 2025, while the oncology endocrinology segment is the fastest growing, with a share of approximately 25.60% in 2024.
• By End-Use, the hospitals segment held approximately 34.50% share in immunodiagnostics market in 2025, while the diagnostic laboratories segment is the fastest growing.

By Product, reagents consumables dominated the immunodiagnostics market, instruments analyzers grew fastest

The reagents consumables segment dominated the product category in 2025, holding approximately 45.60% of total revenue, anchored by the recurring nature of consumable purchases that continue generating steady, predictable revenue across every immunoassay testing cycle. That recurring revenue characteristic keeps reagents and consumables firmly at the top of the broader product segmentation across nearly every major immunodiagnostics laboratory worldwide.

The instruments analyzers segment is projected to grow at the fastest CAGR during the forecast period, as laboratories increasingly upgrade to next-generation automated platforms capable of higher throughput and broader test menus. Rising demand for advanced diagnostic capability continues pushing this product category's growth rate ahead of the broader product segmentation.

By Technology, ELISA dominated the immunodiagnostics market, chemiluminescent immunoassay grew fastest

The ELISA segment dominated the technology category in 2025, holding approximately 36.40% of total revenue, favored for its established reliability, cost-effectiveness, and broad applicability across a wide range of diagnostic testing needs. That established technology base keeps ELISA firmly at the top of the broader technology segmentation across the majority of current immunodiagnostics testing volume worldwide.

The chemiluminescent immunoassay segment is projected to grow at the fastest CAGR during the forecast period, as this technology continues offering superior sensitivity and faster turnaround times relative to traditional ELISA methods, particularly valuable for high-throughput clinical laboratory settings. Rising demand for faster, more sensitive testing continues pushing this technology category's growth rate ahead of the broader technology segmentation.

By Application, infectious diseases dominated the immunodiagnostics market, oncology endocrinology grew fastest

The infectious diseases segment held the largest application share in 2025, at approximately 31.20%, anchored by sustained global testing demand across a wide range of communicable disease screening and diagnosis programs. That broad-based, sustained testing volume keeps infectious diseases firmly at the center of overall immunodiagnostics demand across nearly every major regional healthcare market worldwide.

The oncology endocrinology segment, which held approximately 25.60% share in 2024, is projected to grow at the fastest CAGR during the forecast period, attributed to the adoption of immunodiagnostics in several applications including cancer and endocrine disease detection alongside an increase in new product approvals. Rising cancer diagnosis and monitoring demand, combined with adequate reimbursement for these tests, continues pushing this application category's growth rate ahead of the broader application segmentation.

By End-Use, hospitals dominated the immunodiagnostics market, diagnostic laboratories grew fastest

The hospitals segment held the largest end-use share in 2025, at approximately 34.50%, anchored by comprehensive in-house testing capability that hospitals maintain to support rapid diagnosis and treatment decisions across their patient populations. That comprehensive in-house testing infrastructure keeps hospitals firmly at the top of the broader end-use segmentation across nearly every major immunodiagnostics application category worldwide.

The diagnostic laboratories segment is projected to grow at the fastest CAGR during the forecast period, as centralized reference laboratories increasingly process high-throughput immunoassay testing volumes for multiple healthcare provider networks simultaneously. Rising outsourcing of specialized immunodiagnostic testing continues pushing this end-use category's growth rate ahead of the broader end-use segmentation.

Regional Analysis

North America Immunodiagnostics Market Insights

North America held the largest share of the global Immunodiagnostics Market in 2025, at approximately 37.02%, driven by the rising prevalence of infectious diseases, an increasing number of new product approvals, and the presence of adequate reimbursement for products and tests across the region. Continued biotechnology innovation kept the region firmly ahead of every other region in this market throughout the year.

North America held an important position in the market because it accounted for about 85.60% of regional revenue due to the presence of major players of diagnostic equipment and the complete system of healthcare reimbursement. Also, Canada had been consistently increasing its contribution to regional revenue because of the rising usage of diagnostic tests in it.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Immunodiagnostics Market Insights

Europe held a substantial share of the global Immunodiagnostics Market in 2025, supported by well-established national health insurance coverage and strong biotechnology innovation across the continent. Germany accounted for roughly 27.50% of regional revenue, supported by its concentration of diagnostic companies and advanced healthcare infrastructure.

France, the United Kingdom, and Italy followed a broadly similar trajectory, as continued investment in diagnostic capability extended immunodiagnostics adoption across the continent's largest healthcare markets. Continued regulatory support for early disease detection is expected to keep supporting steady European demand through the remainder of the forecast period.

Asia Pacific Immunodiagnostics Market Insights

Asia Pacific was the fastest-growing region in the global Immunodiagnostics Market, driven by higher potential for intense penetration of advanced immunodiagnostic products and a rising emphasis on early disease detection across the region's largest economies. Rising healthcare infrastructure investment continued driving regional demand at a pace considerably faster than more mature Western markets.

Japan accounted for roughly 35.70% of regional revenue, supported by its advanced healthcare infrastructure and strong emphasis on early disease detection technology adoption. China and South Korea contributed significant additional regional demand through their own expanding diagnostic testing infrastructure, reinforcing Asia Pacific's position as the clear growth leader in this market.

MEA & Latin America Immunodiagnostics Market Insights

Middle East and Africa saw stable growth in the uptake of immunodiagnostics in 2025, thanks to increased investments in healthcare infrastructure and governmental funding in disease screening services in the Gulf countries in particular. The United Arab Emirates contributed about 26.40% to the revenues generated in the region due to their strategy in modernizing healthcare infrastructure and advanced diagnostic technologies.

Latin America expanded at a comparable pace, led by Brazil at roughly 37.30% of regional revenue, where growing healthcare infrastructure investment continued to support category growth. Mexico and Argentina followed a similar trajectory as regional diagnostic testing adoption expanded further through the remainder of the forecast period.

Growth Drivers: Chronic disease burden and personalized medicine adoption

Growing incidence of chronic, infectious, and autoimmune diseases around the world continues to be the central force behind immunodiagnostics market growth. High emphasis on improving diagnostic capabilities and surging demand for early diagnosis continue offering new business scope for immunodiagnostics providers, as the World Health Organization notes that non-communicable diseases were responsible for seventy-one percent of global mortality in 2023.

Advancements in diagnostics technologies and rapidly rising demand for personalized medicine continue increasing demand for immunodiagnostics across nearly every major healthcare market worldwide. Rising utilization of immunodiagnostics in rapid point-of-care testing devices continues expanding access beyond centralized laboratory settings, reinforcing structural demand growth across the broader immunodiagnostics market.

Restraints: Tariff-driven cost pressures and regulatory re-certification burden

Due to the substantial rise in the tariffs of the United States and trade disputes in the spring of 2025, there has been a huge effect on the medical equipment industry, particularly the imports of components needed in diagnostics instruments and disposable plastics. This is due to hospital and clinic complaints of the price increases.

Switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry and adding regulatory complexity to supply chain restructuring decisions. That combined cost and regulatory burden continues requiring manufacturers to pursue dual-sourcing and accelerated domestic production strategies to manage tariff exposure.

Opportunities: Point-of-care expansion and emerging market diagnostic access

Growing utilization of immunodiagnostics in rapid point-of-care testing devices presents substantial opportunity for manufacturers positioned to serve decentralized testing settings beyond traditional hospital and laboratory environments. Manufacturers capable of delivering reliable, easy-to-use point-of-care immunoassay platforms stand to capture a growing share of demand as this testing model continues expanding.

Investing in developing countries presents a further significant growth avenue, as these markets continue offering lucrative opportunities for immunodiagnostics providers seeking to expand access to disease detection technology. Companies capable of delivering affordable, scalable immunodiagnostic solutions stand to capture meaningful new revenue streams as these markets continue developing through 2035.

Recent Developments:

• 2026: DiaSorin, in partnership with QIAGEN, launched the next-generation LIAISON QuantiFERON-TB Gold Plus II assay in the U.S., expanding its immunodiagnostics portfolio with an advanced automated test for latent tuberculosis detection.
• 2025: Roche Diagnostics continued expanding its immunoassay testing portfolio, strengthening its position serving hospitals and laboratories requiring comprehensive infectious disease and oncology biomarker detection capability.
• 2025: Siemens Healthineers continued advancing its automated immunodiagnostics platform technology, targeting laboratories seeking higher-throughput, integrated testing solutions for chronic and infectious disease detection.

Immunodiagnostics Market key players are:

• Abbott Laboratories
• Roche Diagnostics
• DiaSorin S.p.A.
• Danaher Corporation
• QIAGEN N.V.
• bioMérieux SA
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson and Company
• QuidelOrtho Corporation
• Sysmex Corporation
• Revvity, Inc.
• Beckman Coulter, Inc.
• Hologic, Inc.
• Werfen Group
• Fujirebio Inc.
• EUROIMMUN Medizinische Labordiagnostika AG
• OPKO Health, Inc.

Immunodiagnostics Market Report Scope :